Pfizer Sells £2.4 Billion Stake in Haleon, Reducing Holding to 15%

The sale of 640 million shares is part of Pfizer's ongoing plan to gradually reduce its stake in the consumer healthcare company.

Pfizer sold 640 million shares in Haleon at 380p each, reducing its ownership from 22% to 15%.
Haleon bought back £230 million worth of shares from Pfizer as part of a £500 million share buyback program.
Pfizer remains the largest shareholder in Haleon despite the reduction in its stake.
The sale follows earlier transactions, including Pfizer's £2.6 billion sale in March and GSK's complete exit in May.
Haleon continues to streamline its business by selling non-core brands and focusing on higher growth areas.